Judges rule that inventions arrived at by well-established or routine tests can be patented, but the decision will also reassure generics
Following the court’s Abraxis decision, life sciences face a more restrictive interpretation of which products qualify for supplementary protection certificates.
Europe’s highest court has never ruled on whether certificates can be acquired on the basis of a third-party marketing approval – a practice that has given rise to disputes between biopharma innovators
When it comes to litigation strategy, drug businesses have another option to consider in some cases thanks to recent rulings from the courts of England and Wales.
Given the difficulty that pharmaceutical products face when it comes to reaching market, Arrow declarations can be a crucial means of slicing through the knot.
Previous FRAND-related rulings indicate judges in China could set a global rate, would adopt the hard-edged non-discrimination obligation and would consider the parties' negotiation behaviours when reaching their decisions
TCL v Ericsson and Unwired Planet v Huawei send two very different messages to auto companies being approached by patent pools such as Avanci to take SEP licences, says Unified Patents' chief IP counsel Jonathan Stroud
The landmark judgment makes it harder for pharmaceutical companies to use what has become an important source of protection – so opening the way for more generic competition
Justices today considering a much-anticipated case whose outcome could make it harder for pharma companies to obtain such protection in the future
Company now faces possibility of £500 million pay-out to the NHS, while ruling could also make second medical use patents harder to obtain and easier to invalidate
Court of Justice delivers decision that will make it harder for inventors of device-drug combination products to obtain patent term extensions
In upholding the first instance judgment of Mr Justice Birss last week, the Court of Appeals in London has confirmed the UK as a go-to jurisdiction for FRAND-related disputes
Decision to confirm the original Birss judgment is likely to ensure that the UK becomes a major centre for the resolution of FRAND-related disputes
But IAM research shows the NPE led by Boris Teksler is facing a barrage of Chinese invalidity actions from both ZTE and its co-defendant Huawei.
Rare court action from giant telco is further sign of growing monetisation activity in one of hottest areas in tech.